Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C



Document title: Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000411831
ISSN: 1665-2681
Authors: 1
1
1
1
1
1
2
1
Institutions: 1Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León. México
2Universidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, Monterrey, Nuevo León. México
Year:
Season: Ene-Feb
Volumen: 14
Number: 1
Pages: 36-45
Country: México
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract We compared mortality and complications of chronic hepatitis C between treated and untreated Mexican patients after long-term follow-up. We used a time-to-event analysis and identified the prognostic factors. Material and methods. Seventy-four patients with chronic hepatitis C were studied. They were ≥ 18 years of age and had a molecular diagnosis of chronic hepatitis C and ≥ 6 months of follow-up. Patients with neoplasia or those infected with human immunodeficiency virus or hepatitis B Virus were excluded. Kaplan-Meier analysis, log-rank test, annualized incidence per 100 person-years, and stepwise discriminant analysis were used to analyse mortality and complications. Results. The end-point of annualized incidence was lowest in sustained virological responders, intermediate in non-responders, and highest in untreated patients. The absence of treatment impacted adversely on cirrhosis development and the occurrence of portal hypertension and hepatic decompensation/hepatocellular carcinoma (logrank, p < 0.05). Diabetes impacted adversely on liver-related death/liver transplantation among untreated patients. Stepwise discriminant analysis showed that diabetes, high blood pressure, and no retreatment predicted cirrhosis development (eigenvalue ≥ 0.8; p < 0.05). A MELD score ≥ 18 and age ≥ 50 years predicted hepatic decompensation/hepatocellular carcinoma (eigenvalue < 0.8; p < 0.05). APRI ≥ 1.5 predicted mortality/liver transplantation and liver-related death/liver transplantation (eigenvalue < 0.8; p < 0.05). Conclusions. This is the first long-term study of chronic hepatitis C among Mexican patients. Treated patients showed less progression of liver disease. Treated patients showed less progression of liver disease; and older patients, those with metabolic comorbidities, with MELD score ≥ 18 and APRI ≥ 1.5 exhibited adverse effects
Disciplines: Medicina
Keyword: Farmacología,
Gastroenterología,
Hepatitis crónica,
Interferón,
Seguimiento,
Diabetes,
Descompensación hepática
Keyword: Medicine,
Gastroenterology,
Pharmacology,
Chronic hepatitis,
Interferon,
Follow up,
Diabetes,
Hepatic decompensation
Full text: Texto completo (Ver PDF)